Trial reportAIDS care2024
Expectations of preventative benefits and risk behaviors in a randomized trial evaluating oral HIV preexposure prophylaxis candidates.
Jeremy Sugarman, Brian W Weir, Chen Dun, Roy M Gulick, Timothy J Wilkin, Kenneth H Mayer, Marybeth McCauley, Kevin P Weinfurt
Open access · greenAbstract readRandomized Controlled Trial
In one paragraphTrial report in AIDS care, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 93% of its field
1 · What the graph read from itWhat it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
8 authors at 5 institutions in 2 countries.
Brian W WeirDepartment of Health, Behavior and Society, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.ORCID 0000-0003-1634-218X Chen DunDepartment of Biomedical Informatics and Data Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID 0000-0003-4220-5939 Timothy J WilkinDepartment of Medicine, Weill Cornell Medicine, New York, NY, USA.
Kenneth H MayerThe Fenway Institute of Fenway Health and Department of Medicine, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA, USA.
Marybeth McCauleyFHI360, Washington, DC, USA.
Kevin P WeinfurtDepartment of Population Health Sciences, Duke University School of Medicine, Durham, NC, USA.ORCID 0000-0002-0624-7448 Johns Hopkins University · USCornell University · USBeth Israel Deaconess Medical Center · USDuke University · USFamily Health International 360 · US
Funding
Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/UM1AI068636 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, RAJESH T GANDHI · 2011 to 2026
$1073.1MLOC: HIV Prevention Trials NetworkUM1AI068619 · NIAID · FAMILY HEALTH INTERNATIONAL · PI MYRON Scott COHEN, Sinead Delany-Moretlwe · 2011 to 2026
$779.5MStatistical and Data Management Center (SDMC), AIDS Clinical Trials Group (ACTG)UM1AI068634 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Marlene Ann Cooper, Michael David Hughes · 2011 to 2026
$246.6MSDMC: HPTN 084 Pregnancy SupplementUM1AI068617 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Elizabeth Renata Brown, Deborah J Donnell · 2011 to 2026
$204.9MAIDS Clinical Trials Group NetworkU01AI068636 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI KURITZKES, DANIEL R. · 2006 to 2010
$147.1MLC: HIV Prevention Trials Network - Laboratory Support for the SARS-CoV-2 Seroprevalence Study (CoVPN 5002)UM1AI068613 · NIAID · JOHNS HOPKINS UNIVERSITY · PI SUSAN H ESHLEMAN, Mark A Marzinke · 2011 to 2026
$100.2MWeill Cornell Medicine - Rutgers New Jersey Medical School Clinical Trials UnitUM1AI069419 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI ROY M. GULICK · 2012 to 2026
$44.6MPREMIS: Preventive Misconception in HIV Prevention TrialsR21MH092253 · NIMH · DUKE UNIVERSITY · PI SUGARMAN, JEREMY, WEINFURT, KEVIN P · 2010 to 2011
$448kNIAID NIH HHS U01 AI068636NIAID NIH HHS UM1 AI068613NIAID NIH HHS UM1 AI068617NIAID NIH HHS UM1 AI068619NIAID NIH HHS UM1 AI068634NIAID NIH HHS UM1 AI068636NIAID NIH HHS UM1 AI069419NIMH NIH HHS R21 MH092253
6 · The paper itselfAbstract
When participants enrolled in an HIV prevention trial hold a preventive misconception (PM) - expectations that experimental interventions will confer protection from HIV infection - they may engage in behaviors that increase their risk of acquiring HIV. This can raise ethical concerns about whether those enrolled in the trial understand the nature of participation and their safety. Consequently, we systematically evaluated the prevalence of PM and its association with risk behaviors in a trial examining three candidate regimens for oral HIV pre-exposure prophylaxis in which all participants received at least one antiretroviral agent. Overall, trial participants exhibited relatively high preventive expectations that may be associated with an increase in risk behaviors among men who have sex with men. In addition, we identified substantial site variability in PM that necessitates future research to uncover its source. This will allow appropriate measures to be taken to mitigate PM and help ensure that participants have an accurate understanding of the potential risks and benefits of trial participation throughout the course of a trial.
Indexed as
Anti-HIV AgentsHIV InfectionsPre-Exposure ProphylaxisRisk-TakingAdministration, OralAdultFemaleHealth Knowledge, Attitudes, PracticeHomosexuality, MaleHumansMaleMiddle AgedSexual BehaviorAnti-HIV AgentsbehaviorsethicsHIV preventionpreventive misconceptionSDG 3: Good health and well-being
Identifiers
PMID38606559
PMCPMC11288779
OpenAlexW4394754146
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390